Next generation ALK inhibitor for ALK-rearranged non–small cell lung cancer

A new drug ceritinib appears to be effective against advanced ALK-positive NSCLC, both in tumours that have become resistant to crizotinib and in those never treated with it, with mostly mild and manageable side effects. The results of a phase I clinical trial conducted at centers in 11 countries are reported in the New England Journal of Medicine. Read more here.